REFERENCES
1.
Eisenberg DM, Davis RB, Ettner SL, et al: Trends
in alternative medicine use in the United States, 1990–1997. JAMA 280:1569,
1998.
2.
Ang-Lee MK, Moss J, Yuan CS: Herbal medicines and
perioperative care. JAMA 286:208, 2001.
3.
National Center for Complementary and Alternative
Medicine. http://nccam.nih.gov/health/whatiscam/ Accessed August 15, 2003.
4.
Tsen LC, Segal S, Pothier M, et al: Alternative
medicine use in presurgical patients. Anesthesiology 93:148, 2000.
5.
Kaye AD, Clarke RC, Sabar R, et al: Herbal medications:
Current trends in anesthesiology practice—A hospital survey. J Clin Anesth
12:468, 2000.
6.
Leung JM, Dzankic S, Manku K, et al: The prevalence
and predictors of the use of alternative medicine in presurgical patients in five
California hospitals. Anesth Analg 93:1062, 2001.
7.
Weinrobe MC, Montgomery B: Acquired bleeding diathesis
in a patient taking PC-SPES. N Engl J Med 347:1213, 2001.
8.
De Smet P: Herbal remedies. N Engl J Med 347:2046,
2002.
9.
NBJ's herbal and botanical U.S. consumer sales.
http://store.yahoo.com/nbj/new2019top75.html/Accessed November 24, 2003.
10.
Gruenwald J (ed): Physicians' Desk Reference for
Herbal Medicines, 2nd ed. Montvale, NJ, Medical Economics, 2000.
11.
Blumenthal M, Busse WR, Goldberg A for the German
Federal Institute for Drugs and Medical Devices Commission E, American Botanical
Council, and Integrative Medical Communications (eds): The Complete German Commission
E Monographs: Therapeutic Guide to Herbal Medicines. Boston, Integrative Medicine
Communications, 1998.
12.
Yuan CS, Bieber EJ (eds): Textbook of Complementary
and Alternative Medicine. New York, Parthenon, 2003.
13.
Kassler WJ, Blanc P, Greenblatt R: The use of
medicinal herbs by human immunodeficiency virus-infected patients. Arch Intern Med
151:2281, 1991.
14.
Cirigliano M, Sun A: Advising patients about herbal
therapies. JAMA 280:1565, 1998.
15.
Leak JA: Herbal medicines: What do we need to
know? ASA Newsletter 64:6–7, 2000.
16.
Kennedy JM, van Rij AM, Spears GF, et al: Polypharmacy
in a general surgical unit and consequences of drug withdrawal. Br J Clin Pharmacol
49:353, 2000.
17.
Tonnesen H, Rosenberg J, Nielsen HJ, et al: Effect
of preoperative abstinence on poor postoperative outcome in alcohol misusers: Randomized
controlled trial. BMJ 318:1311, 1999.
18.
Melchart D, Linde K, Fischer P, Kaesmayr J: Echinacea
for preventing and treating the common cold [review]. Cochrane Database Syst Rev
2:CD000530, 2000.
19.
Pepping J: Echinacea. Am J Health Syst Pharm
56:121, 1999.
20.
See DM, Broumand N, Sahl L, et al: In vitro effects
of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity
in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome
patients. Immunopharmacology 35:229, 1997.
21.
Rehman J, Dillow JM, Carter SM, et al: Increased
production of antigen-specific immunoglobulins G and M following in vivo treatment
with the medicinal plants Echinacea angustifolia
and Hydrastis canadensis. Immunol Lett 68:391, 1999.
22.
Mullins RJ: Echinacea-associated anaphylaxis.
Med J Aust 168:170, 1998.
23.
Boullata JI, Nace AM: Safety issues with herbal
medicine. Pharmacotherapy 20:257, 2000.
24.
Blanck HM, Khan LK, Serdula MK: Use of nonprescription
weight loss products. JAMA 286:930, 2001.
25.
Bent S, Tiedt TN, Odden MC, et al: The relative
safety of ephedra compared with other herbal products. Ann Intern Med 138:468, 2003.
26.
Haller CA, Benowitz NL: Adverse cardiovascular
and central nervous system events associated with dietary supplements containing
ephedra alkaloids. N Engl J Med 343:1833, 2000.
27.
Zaacks SM, Klein L, Tan CD, et al: Hypersensitivity
myocarditis associated with ephedra use. J Toxicol Clin Toxicol 37:485, 1999.
28.
Blau JJ: Ephedrine nephrolithiasis associated
with chronic ephedrine abuse. J Urol 160:825, 1998.
29.
Powell T, Hsu FF, Turk J, et al: Ma-huang strikes
again: Ephedrine nephrolithiasis. Am J Kidney Dis 32:153, 1998.
30.
White LM, Gardner SF, Gurley BJ, et al: Pharmacokinetics
and cardiovascular effects of ma-huang (Ephedra sinica)
in normotensive adults. J Clin Pharmacol 37:116, 1997.
31.
Gurley BJ. Gardner SF, White LM, et al: Ephedrine
pharmacokinetics after the ingestion of nutritional supplements containing Ephedra
sinica (ma huang). Ther Drug Monit 20:439, 1998.
32.
Stevinson C, Pittler MH, Ernst E: Garlic for treating
hypercholesteremia: A meta-analysis of randomized clinical trials. Ann Intern Med
133:420, 2000.
33.
Agarwal KC: Therapeutic actions of garlic constituents.
Med Res Rev 16:111, 1996.
34.
Mohammad SF, Woodward SC: Characterization of
a potent inhibitor of platelet aggregation and release reaction isolated from Allium
sativum (garlic). Thromb Res 44:793, 1986.
35.
Srivastava KC: Evidence for the mechanism by which
garlic inhibits platelet aggregation. Prostaglandins Leukot Med 22:313, 1986.
36.
Ariga T, Oshiba S, Tamada T: Platelet aggregation
inhibitor in garlic. Lancet 1:150, 1981.
37.
Boullin DJ: Garlic as a platelet inhibitor. Lancet
1:776, 1981.
38.
Apitz-Castro R, Escalante J, Vargas R, et al:
Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory
action of prostacyclin, forskolin, indomethacin and dipyridamole on human platelets.
Thromb Res 42:303, 1986.
39.
Ali M, Al-Qattan KK, Al-Enezi F, et al: Effect
of allicin from garlic powder on serum lipids and blood pressure in rats fed with
a high cholesterol diet. Prostaglandins Leukot Essent Fatty Acids 62:253, 2000.
40.
Apitz-Castro R, Ledezma E, Escalante J, et al:
The molecular basis of the antiplatelet action of ajoene: Direct interaction with
the fibrinogen receptor. Biochem Biophys Res Commun 141:145, 1986.
41.
Makheja AN, Bailey JM: Antiplatelet constituents
of garlic and onion. Agents Actions 29:360, 1990.
42.
Gebhardt R: Multiple inhibitory effects of garlic
extracts on cholesterol biosynthesis in hepatocytes. Lipids 28:613, 1993.
43.
Harenberg J, Giese C, Zimmermann R: Effect of
dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol
level in patients with hyperlipoproteinemia. Atherosclerosis 74:247, 1988.
44.
Chutani SK, Bordia A: The effect of fried versus
raw garlic on fibrinolytic activity in man. Atherosclerosis 38:417, 1981.
45.
Rose KD, Croissant PD, Parliamet CF, et al: Spontaneous
spinal epidural hematoma with associated platelet dysfunction from excessive garlic
ingestion: A case report. Neurosurgery 26:880, 1990.
46.
Le Bars PL, Katz MM, Berman N, et al: A placebo-controlled,
double-blind, randomized trial of an extract of Ginkgo biloba
for dementia. JAMA 278:1327, 1997.
47.
Oken BS, Storzbach DM, Kaye JA: The efficacy of
Ginkgo biloba on cognitive function in Alzheimer
disease. Arch Neurol 55:1409, 1998.
48.
Solomon PR, Adams F, Silver A, et al: Ginkgo for
memory enhancement: A randomized controlled trial. JAMA 288:835, 2002.
49.
Jung F, Mrowietz C, Kiesewetter H, et al: Effect
of Ginkgo biloba on fluidity of blood and peripheral
microcirculation in volunteers. Arzneimittelforschung 40:589, 1990.
50.
Maitra I, Marcocci L, Droy-Lefaix MT, et al: Peroxyl
radical scavenging activity of Ginkgo biloba extract
EGb 761. Biochem Pharmacol 49:1649, 1995.
51.
Hoyer S, Lannert H, Noldner M, et al: Damaged
neuronal energy metabolism and behavior are improved by Ginkgo
biloba extract (EGb 761). J Neural Transm 106:1171, 1999.
52.
Huguet F, Tarrade T: Alpha 2-adrenoceptor changes
during cerebral aging. The effect of Ginkgo biloba
extract. J Pharm Pharmacol 44:24, 1992.
53.
Chung KF, Mccusker M, Page CP, et al: Effect of
a ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet
activating factor in man. Lancet 1:248, 1987.
54.
Fessenden JM, Wittenborn W, Clarke L: Ginkgo
biloba: A case report of herbal medicine and bleeding postoperatively
from a laparoscopic cholecystectomy. Am Surg 67:33, 2001.
55.
Rowin J, Lewis SL: Spontaneous bilateral subdural
hematomas associated with chronic Ginkgo biloba ingestion.
Neurology 46:1775, 1996.
56.
Vale S: Subarachnoid haemorrhage associated with
Ginkgo biloba. Lancet 352:36, 1998.
57.
Gilbert GJ: Ginkgo biloba.
Neurology 48:1137, 1997.
58.
Matthews MK: Association of Ginkgo
biloba with intracerebral hemorrhage. Neurology 50:1933, 1998.
59.
Rosenblatt M, Mindel J: Spontaneous hyphema associated
with ingestion of Ginkgo biloba extract. N Engl
J Med 336:1108, 1997.
60.
Gregory PJ: Seizure associated with Ginkgo
biloba. Ann Intern Med 134:344, 2001.
61.
Mills S, Bone K (eds): Ginkgo. In
Principles and Practice of Phytotherapy. New York, Churchill Livingstone, 2000.
62.
Brekham II, Dardymov IV: New substances of plant
origin which increase nonspecific resistance. Annu Rev Pharmacol 9:419, 1969.
63.
Attele AS, Wu JA, Yuan CS: Ginseng pharmacology:
Multiple constituents and multiple actions. Biochem Pharmacol 58:1685, 1999.
64.
Vogler BK, Pittler MH, Ernst E: The efficacy of
ginseng. A systematic review of randomized clinical trials. Eur J Clin Pharmacol
55:567, 1999.
65.
Attele AS, Zhou YP, Xie JT, et al: Antidiabetic
effects of Panax ginseng berry extract and the identification
of an effective component. Diabetes 51:1851, 2002.
66.
Vuksan V, Sievenpiper JL, Koo V, et al: American
ginseng (Panax quinquefolius L) reduces postprandial
glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch
Intern Med 160:1009, 2000.
67.
Kimura Y, Okuda H, Arichi S: Effects of various
ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets.
J Pharm Pharmacol 40:838, 1988.
68.
Kuo SC, Teng CM, Lee JC, et al: Antiplatelet components
in Panax ginseng. Planta Med 56:164, 1990.
69.
Park HJ, Lee JH, Song YB, et al: Effects of dietary
supplementation of lipophilic fraction from Panax ginseng
on cGMP and cAMP in rat platelets and on blood coagulation. Bio Pharm Bull 19:1434,
1996.
70.
Teng CM, Kuo SC, Ko FN, et al: Antiplatelet actions
of panaxynol and ginsenosides isolated from ginseng. Biochim Biophys Acta 990:315,
1989.
71.
Janetzky K, Morreale AP: Probable interaction
between warfarin and ginseng. Am J Health Syst Pharm 54:692, 1997.
72.
Chen SE, Sawchuk RJ, Staba EJ: American ginseng.
III. Pharmacokinetics of ginsenosides in the rabbit. Eur J Drug Metab Pharmacokinet
5:161, 1980.
73.
Pittler MH, Ernst E: Efficacy of kava extract
for treating anxiety: Systematic review and meta-analysis. J Clin Psychopharmacol
20:84, 2000.
74.
Pepping J: Kava: Piper methysticum.
Am J Health Syst Pharm 56:957, 1999.
75.
Yuan CS, Dey L, Wang A, et al: Kavalactones and
dihydrokavain modulate GABAergic activity in a rat gastricbrainstem preparation.
Planta Med 68:1092, 2002.
76.
Jamieson DD, Duffield PH, Cheng D, et al: Comparison
of the central nervous system activity of the aqueous and lipid extract of kava (Piper
methysticum). Arch Int Pharmacodyn 301:66, 1989.
77.
Keledjian J, Duffield PH, Jamieson DD, et al:
Uptake into mouse brain of four compounds present in the psychoactive beverage kava.
J Pharm Sci 77:1003, 1988.
78.
Almeida JC, Grimsley EW: Coma from the health
food store: Interaction between kava and alprazolam. Ann Intern Med 125:940, 1996.
79.
Ernst E: Second thoughts about kava. Am J Med
113:347, 2002.
80.
Berry SL, Coffey DS, Walsh PC, et al: The development
of human benign prostatic hyperplasia with age. J Urol 132:474, 1984.
81.
Buck A: Phytotherapy for the prostate. Br J Urol
78:325, 1996.
82.
Gerber GS: Saw palmetto for the treatment of men
with lower urinary tract symptoms. J Urol 163:1408, 2000.
83.
Iehle C, Delos S, Guirou O, et al: Human prostatic
steroid 5 alpha-reductase isoforms: A comparative study of selective inhibitors.
J Steroid Biochem Mol Biol 54:273, 1995.
84.
Plosker GL, Brogden RN: Serenoa
repens (Permixon). A review of its pharmacology and therapeutic efficacy
in benign prostatic hyperplasia. Drugs Aging 9:379, 1996.
85.
Di Silverio F, D'Eramo G, Lubrano C, et al: Evidence
that Serenoa repens extract displays an antiestrogenic
activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol
21:309, 1992.
86.
Vacher P, Prevarskaya N, Skyrma R, et al: The
lipidosterolic extract from Serenoa repens interferes
with prolactin receptor signal transduction. J Biomed Sci 2:357, 1995.
87.
Paubert-Braquet M, Cousse H, Raynaud JP, et al:
Effect of the lipidosterolic extract of Serenoa repens
(Permixon) and its major components on basic fibroblast growth factor-induced proliferation
of cultures of human prostate biopsies. Eur Urol 33:340, 1998.
88.
Vacherot F, Azzouz M, Gil-Diez-de-Medina S, et
al: Induction of apoptosis and inhibition of cell proliferation by the lipidosterolic
extract of Serenoa repens (LSESr, Permixon) in benign
prostatic hyperplasia. Prostate 45:259, 2000.
89.
Goepel M, Hecker U, Krege S, et al: Saw palmetto
extracts potently and noncompetitively inhibit human alpha-1-adrenoceptors in vitro.
Prostate 38:208, 1999.
90.
Brue W, Hagenlocer M, Redl K, et al: Anti-inflammatory
activity of sabal fruit extracts prepared with supercritical carbon dioxide. In
vitro antagonists of cyclooxygenase and 5-lipooxygenase metabolism. Arzneimittelforschung
42:547, 1992.
91.
Paubert-Braquet M, Mencia Huerta JM, Cousse H,
et al: Effect of the lipidic lipidosterolic extract of Serenoa
repens (Permixon) on the ionophore A23187-stimulated production of leukotriene
B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent
Fatty Acids 57:299, 1997.
92.
Cheema P, El-Mefty O, Jazieh AR: Intraoperative
haemorrhage associated with the use of extract of saw palmetto herb: A case report
and review of literature. J Intern Med 250:167, 2001.
93.
Gaster B, Holroyd J: St. John's wort for depression:
A systematic review. Arch Intern Med 160:152, 2000.
94.
Lecrubier Y, Clerc G, Didi R, et al: Efficacy
of St. John's wort extract WS 5570 in major depression: A double-blind, placebo-controlled
trial. Am J Psychiatry 159:1361, 2002.
95.
Shelton RC, Keller MB, Gelenberg A, et al: Effectiveness
of St. John's wort in major depression. JAMA 285:1978, 2001.
96.
Hypericum Depression Trial Study Group: Effect
of Hypericum perforatum (St. John's wort) in major
depressive disorder: A randomized controlled trial. JAMA 287:1807, 2002.
97.
Muller WE, Singer A, Wonnemann M, et al: Hyperforin
represents the neurotransmitter reuptake-inhibiting constituent of Hypericum
extract. Pharmacopsychiatry 31(Suppl 1):16, 1998.
98.
Neary JT, Bu Y: Hypericum LI 160 inhibits uptake
of serotonin and norepinephrine in astrocytes. Brain Res 816:358, 1999.
99.
Franklin M, Chi J, McGavin C, et al: Neuroendocrine
evidence for dopaminergic actions of Hypericum extract
(PI 160) in healthy volunteers. Biol Psychiatry 46:581, 1999.
100.
Suzuki O, Katsumata Y, Oya M, et al: Inhibition
of monoamine oxidase by hypericin. Planta Med 50:272, 1984.
101.
Yu PH: Effect of the Hypericum
perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry
33:60, 2000.
102.
Muller WE, Rolli M, Schafer C, et al: Effects
of Hypericum extract (LI 160) in biochemical models
of antidepressant activity. Pharmacopsychiatry 30(Suppl 2):102, 1997.
103.
Lantz MS, Buchalter E, Giambanco V: St. John's
wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol
12:7, 1999.
104.
Ernst E: Second thoughts about safety of St.
John's wort. Lancet 354:2014, 1999.
105.
Piscitelli SC, Burstein AH, Chaitt D, et al:
Indinavir concentrations and St. John's wort. Lancet 355:547, 2000.
106.
Yue QY, Bergquist C, Gerden B: Safety of St.
John's wort. Lancet 355:576, 2000.
107.
Breidenbach T, Hoffmann MW, Becker T, et al:
Drug interaction of St. John's wort with cyclosporine. Lancet 355:1912, 2000.
108.
Ruschitzka F, Meier PJ, Turina M, et al: Acute
heart transplant rejection due to Saint John's wort. Lancet 355:548, 2000.
109.
Johne A, Brockmoller J, Bauer S, et al: Pharmacokinetic
interaction of digoxin with an herbal extract from St. John's wort (Hypericum
perforatum). Clin Pharmacol Ther 66:338, 1999.
110.
Crowe S, McKeating K: Delayed emergence and St.
John's wort. Anesthesiology 96:1025, 2002.
111.
Kerb R, Brockmoller J, Staffeldt B, et al: Single-dose
and steady-state pharmacokinetics of hypericin and pseudo hypericin. Antimicrob
Agents Chemother 40:2087, 1996.
112.
Biber A, Fischer H, Romer A, et al: Oral bioavailability
of hyperforin from Hypericum extracts in rats and
human volunteers. Pharmacopsychiatry 31(Suppl 1):36, 1998.
113.
Houghton PJ: The scientific basis for the reputed
activity of valerian. J Pharm Pharmacol 51:505, 1999.
114.
Hendriks H, Bos R, Allersma DP, et al: Pharmacological
screening of valerenal and some other components of essential oil of Valeriana
officinalis. Planta Med 42:62, 1981.
115.
Ortiz JG, Nieves-Natal J, Chavez P: Effects of
Valeriana officinalis extracts on [3H] flunitrazepam
binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem
Res 24:1373, 1999.
116.
Leuschner J, Muller J, Rudmann M: Characterization
of the central nervous depressant activity of a commercially available valerian root
extract. Arzneimittelforschung 43:638, 1993.
117.
Andreatini R, Leite JR: Effect of valepotriates
on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur
J Pharmacol 260:233, 1994.
118.
Garges HP, Varia I, Doraiswamy PM: Cardiac complications
and delirium associated with valerian root withdrawal. JAMA 280:1566, 1998.
119.
Bjornsson TD, Nash PV, Schaten R: The anticoagulant
effect of chondroitin-4-sulfate. Thromb Res 27:15, 1982.
120.
Pritchard NR, Kalra PA: Renal dysfunction accompanying
oral creatine supplements. Lancet 351:1252, 1998.
121.
Hanania M, Kitain E: Melatonin for treatment
and prevention of postoperative delirium. Anesth Analg 94:338, 2002.
122.
NIH Consensus Conference. Acupuncture [review].
JAMA 280:1518, 1998.
123.
Kaptchuk TJ: Acupuncture: Theory, efficacy,
and practice. Ann Intern Med 136:374, 2002.
124.
Tsunoda Y, Sakahira K, Nakano S, et al: Antagonism
of acupuncture analgesia by naloxone in unconscious man. Bull Tokyo Med Dent Univ
27:89, 1980.
125.
Wu MT, Hsieh JC, Xiong J, et al: Central nervous
pathway for acupuncture stimulation: Localization of processing with functional
MR imaging of the brain—Preliminary experience. Radiology 212:133, 1999.
126.
Hui KK, Liu J, Makris N, et al: Acupuncture modulates
the limbic system and subcortical gray structures of the human brain: Evidence from
fMRI studies in normal subjects. Hum Brain Mapp 9:13, 2000.
127.
Hsieh JC, Tu CH, Chen FP, et al: Activation of
the hypothalamus characterizes the acupuncture stimulation at the analgesic point
in human: A positron emission tomography study. Neurosci Lett 307:105, 2001.
128.
Biella G, Sotgiu ML, Pellegata G, et al: Acupuncture
produces central activations in pain regions. Neuroimage 14:60, 2001.
129.
Mori H, Nishijo K, Kawamura H, et al: Unique
immunomodulation by electro-acupuncture in humans possibly via stimulation of the
autonomic nervous system. Neurosci Lett 320:21, 2002.
130.
Son YS, Park HJ, Kwon OB, et al: Antipyretic
effects of acupuncture on the lipopolysaccharide-induced fever and expression of
interleukin-6 and interleukin-1 beta mRNAs in the hypothalamus of rats. Neurosci
Lett 319:45, 2002.
131.
Guo HF, Tian J, Wang X, et al: Brain substrates
activated by electroacupuncture (EA) of different frequencies (II): Role of Fos/Jun
proteins in EA-induced transcription of preproenkephalin and preprodynorphin genes.
Brain Res Mol Brain Res 43:167, 1996.
132.
Gerhard I, Postneek F: Auricular acupuncture
in the treatment of female infertility. Gynecol Endocrinol 6:171, 1992.
133.
Agarwal A, Bose N, Gaur A, et al: Acupressure
and ondansetron for PONV after laparoscopic cholecystectomy. Can J Anaesth 49:554,
2002.
134.
Alkaissi A, Evertsson K, Johnsson VA, et al:
P6 acupressure may relieve nausea and vomiting after gynecological surgery: An effectiveness
study in 410 women. Can J Anaesth 49:1034, 2002.
135.
Alkaissi A, Stalnert M, Kalman S: Effect and
placebo effect of acupressure P6 on nausea and vomiting after outpatient gynaecological
surgery. Acta Anaesthesiol Scand 43:270, 1999.
136.
Boehler M, Mitterschiffthaler G, Schlager A:
Korean hand acupressure reduces postoperative nausea and vomiting after gynecological
laparoscopic surgery. Anesth Analg 94:872, 2002.
137.
Harmon D, Gardiner J, Harrison R, et al: Acupressure
and the prevention of nausea and vomiting after laparoscopy. Br J Anaesth 82:387,
1999.
138.
Harmon D, Ryan M, Kelly A, et al: Acupressure
and prevention of nausea and vomiting during and after spinal anesthesia for caesarean
section. Br J Anaesth 84:463, 2000.
139.
Rusy LM, Hoffman GM, Weisman SJ: Electroacupuncture
prophylaxis of postoperative nausea and vomiting following pediatric tonsillectomy
with or without adenoidectomy. Anesthesiology 96:300, 2002.
140.
Schlager A, Boehler M, Puhringer F: Korean hand
acupressure reduces postoperative nausea and vomiting in children after strabismus
surgery. Br J Anaesth 85:267, 2000.
141.
Schlager A, Offer T, Baldissera I: Laser stimulation
of acupuncture point P6 reduces postoperative vomiting in children undergoing strabismus
surgery. Br J Anaesth 81:529, 1998.
142.
Wang SM, Kain ZN: P6 acupoint injections are
as effective as droperidol in controlling early postoperative nausea and vomiting
in children. Anesthesiology 97:359, 2002.
143.
Zarate E, Mingus M, White PF, et al: Use of transcutaneous
acupoint electrical stimulation for preventing nausea and vomiting after laparoscopic
surgery. Anesth Analg 92:629, 2001.
144.
Lee A, Done ML: The use of nonpharmacologic techniques
to prevent postoperative nausea and vomiting: A meta-analysis. Anesth Analg 88:1362,
1999.
145.
Dundee JW, Ghaly RG: Does the timing of P6 acupuncture
influence its efficacy as a postoperative antiemetic? Br J Anaesth 63:630, 1989.
146.
Koch ME, Kain ZN, Ayoub C, et al: The sedative
and analgesic sparing effect of music. Anesthesiology 89:300, 1998.
147.
Wang SM, Kulkarni L, Dolev J, et al: Music and
preoperative anxiety: A randomized, controlled study. Anesth Analg 94:1489, 2002.
148.
Kain ZN, Wang SM, Mayes LC, et al: Sensory stimuli
and anxiety in children undergoing surgery: A randomized, controlled trial. Anesth
Analg 92:897, 2001.
149.
Cruise CJ, Chung F, Yogendran S, et al: Music
increases satisfaction in elderly outpatients undergoing cataract surgery. Can J
Anaesth 44:43, 1997.
